<DOC>
	<DOCNO>NCT02499783</DOCNO>
	<brief_summary>This study evaluate efficacy safety adalimumab induction maintenance treatment subject moderately severely active Crohn 's disease .</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy Adalimumab Chinese Subjects With Moderate Severe Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Subjects Chinese descent full Chinese parentage . Diagnosis Crohn 's disease ( CD ) least 3 month prior Week 0 . Crohn 's Disease Activity Index ( CDAI ) great equal 220 less equal 450 despite treatment oral corticosteroid and/or immunosuppressant . Subject negative Tuberculosis ( TB ) Screening Assessment . Subject elevate high sensitivity Creactive protein ( hsCRP ) Screening Period . Subject ulcerative colitis indeterminate colitis . Subject surgical bowel resection within past 6 month plan resection time point future . Subject ostomy ileoanal pouch . Subject short bowel syndrome . Subject symptomatic know obstructive stricture . Subject internal external fistula ( exception anal fistula without abscess ) . Active , chronic recur infection , active tuberculosis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Biologic</keyword>
	<keyword>China</keyword>
	<keyword>Tumor necrosis factor ( TNF ) -alpha</keyword>
</DOC>